EP Patent

EP2408302A1 — Ophthalmic formulations of ketotifen and methods of use

Assigned to Aciex Therapeutics Inc · Expires 2012-01-25 · 14y expired

What this patent protects

The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of t…

USPTO Abstract

The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of such treatment by topical application of the ketotifen formulations of the invention to the eye of a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP2408302A1
Jurisdiction
EP
Classification
Expires
2012-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Aciex Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.